Cardiovascular disease risk in schizophrenia patients: a case control study
Kedar B Joshi1, Anup Nillawar2, A P Thorat3
1Assistant Professor, Department of Biochemistry GMC Aurangabad, Maharashtra, India .
Insights
Schizophrenia patients exhibit elevated cardiovascular disease risk factors, including metabolic syndrome and dyslipidemia. Early monitoring for these cardiovascular disease risks is crucial for timely intervention in schizophrenia patients.
Area of Science:
- Psychiatry and Cardiology
- Clinical Research
Background:
- Schizophrenia patients face increased risks of cardiovascular morbidity and mortality.
- Understanding cardiovascular disease (CVD) risk in schizophrenia is critical.
Purpose of the Study:
- To quantify CVD risk parameters in schizophrenia patients.
- To compare CVD risk factors between schizophrenia patients and a healthy control group.
Main Methods:
- A case-control study involving 45 schizophrenia patients and 41 healthy controls.
- Measurement of body mass index, metabolic syndrome, lipid parameters, and high-sensitivity C-reactive protein (hs-CRP).
- Assessment of metabolic syndrome and dyslipidemia based on NCEP ATP III guidelines.
Main Results:
- Schizophrenia subjects had significantly higher waist circumference, triglycerides, and hs-CRP.
- Lower HDL cholesterol levels were observed in schizophrenia patients.
- Prevalence of metabolic syndrome (28.8%) and dyslipidemia (51.1%) was higher in the schizophrenia group.
Conclusions:
- Schizophrenia patients have a heightened risk of cardiovascular events due to prevalent metabolic syndrome and dyslipidemia.
- Regular monitoring of CVD risk factors is recommended for schizophrenia patients.
- Timely physician referral for management of CVD risks in schizophrenia is essential.
Background:
The Schizophrenia patients are at higher risk for cardiovascular morbidity and mortality. The aim of this case-control study is to measure Cardiovascular Disease (CVD) risk parameters in patient group and compare it with normal population.
Methodology:
We recruited 45 cases of Schizophrenia diagnosed by diagnostic and statistical manual of mental disorders (DSM-IV) criteria and 41 healthy controls from general population. The body mass index, metabolic syndrome parameters, lipid parameters and high sensitive C-reactive protein were measured in both groups. Metabolic syndrome and dyslipidemia prevalence were assessed based on National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guidelines.
Results:
The Schizophrenia subjects showed statistically significant high waist circumference, increased triglycerides and decreased HDL cholesterol values. The subjects also showed statistically significant increased hs-CRP values. The prevalence of metabolic syndrome and laboratory dyslipidemia were 28.8% and 51.1% respectively, which were higher compared to control group.
Conclusion:
The Schizophrenia subjects are at higher risk for cardiovascular disease events due to high prevalence of metabolic syndrome and dyslipidemia. These patients should be regularly monitored for CVD risk factors and timely referred to physician for further management.
More Related Videos
05:14Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Related Concept Videos
Psychological and Sociocultural Causes of Schizophrenia
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Schizophrenia
Coronary Artery Disease I: Introduction
